ONCO ONCO
Company Profile ↓Company Overview
ONCO (ONCO) is a publicly traded company listed on with a market capitalization of $31.20K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.31.
Recent Developments
- Dec 2025 Revenue of $815.37K (-67.7% YoY); net profit $-14.03M.
- Trailing 12 Months Year-on-year growth — revenue -67.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -67.70% |
Stock Price Performance
| 1 Year: | -99.37% |
| 6 Months: | -98.64% |
| 3 Months: | -80.67% |
| 1 Month: | -6.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.44 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 704.85K | 406.86K | - | 101.63K | 106.49K | 303.65K | 303.60K | 21.46K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.80K | 35.99K | 34.76K | 55.91K | 23.11K |
| Gross Profit | - | - | - | - | - | - | - | - | - | 189.00K | 100.72K | 105.41K | - | 45.83K | 70.50K | 268.89K | 247.68K | -1.66K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 1.41M | 2.34M | 1.53M | 2.09M |
| Operating Income | -325.78K | -792.27K | -1.10M | -2.07M | -4.29M | -3.87M | -2.85M | -6.65M | -4.49M | -11.08M | -13.62M | -2.65M | - | -1.65M | -1.34M | -2.07M | -1.28M | -2.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.32M | -2.15M | -8.48M | 5.68M | -4.21M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 223.59K | 223.10K | 300.07K | 4.25K | 2.24K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.55M | -2.37M | -8.78M | 5.67M | -4.21M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 525 | 0 |
| Net Income | -325.78K | -792.27K | -1.10M | -2.07M | -4.26M | -3.87M | -2.85M | -6.87M | -5.35M | -11.12M | -14.31M | -3.83M | - | -8.55M | -2.37M | -8.78M | 5.67M | -4.21M |
| Diluted EPS | - | -0.29 | -0.40 | -0.34 | -0.36 | -0.27 | -0.18 | -0.43 | -12.21 | -20.08 | -2,191.59 | -249.08 | - | -2,272.50 | -238.00 | -312.50 | - | -67.10 |
| R&D Expense | 88.24K | 529.54K | 269.93K | 455.09K | 1.29M | 1.18M | 1.08M | 846.85K | 219.24K | 48.96K | - | 109.36K | - | 24.45K | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 58.47K | 2.52M | 815.37K |
| Cost of Revenue | - | 0 | 1.19M | 1.47M | 182.46K |
| Gross Profit | - | 0 | -1.13M | 1.06M | 632.91K |
| Operating Expenses | - | 13.48M | 16.72M | 11.39M | 6.98M |
| Operating Income | - | -13.48M | -17.85M | -10.33M | -6.34M |
| EBITDA | - | -13.41M | -36.71M | -57.60M | -13.27M |
| Interest Expense | - | 0 | 671.62K | 1.41M | 751.00K |
| Pretax Income | - | -13.42M | -37.42M | -59.74M | -14.03M |
| Tax Provision | - | 0 | -12.59K | -1.05M | 525 |
| Net Income | - | -13.42M | -37.41M | -58.69M | -14.03M |
| Diluted EPS | - | -151,867.29 | -285,570.18 | -21,301.06 | -828.00 |
| R&D Expense | 1.33M | 4.13M | 1.95M | 154.36K | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 26.31M | 87.52M | 28.18M | 24.93M |
| Current Assets | - | - | 26.26M | 5.84M | 950.27K | 6.07M |
| Cash & Equivalents | - | - | 25.75M | 4.55M | 646.50K | 5.22M |
| Inventory | - | - | 0 | 364.05K | 64.08K | 149.96K |
| Receivables | - | - | 0 | 149.73K | 25.72K | 296.87K |
| Total Liabilities | - | - | 3.92M | 86.11M | 18.57M | 9.16M |
| Current Liabilities | - | - | 3.92M | 17.19M | 18.29M | 9.14M |
| Long Term Debt | - | - | - | 118.86K | - | - |
| Total Debt | - | - | 0 | 9.89M | 9.45M | 48.77K |
| Total Equity | 4.73M | - | 22.39M | -5.60M | 9.61M | 15.77M |
| Shares Outstanding | - | - | 91 | 134 | 2.77K | 31.20K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.68M | -13.58M | -10.50M | -9.68M |
| Investing Cash Flow | - | -32.66K | -8.65M | -28.47K | 0 |
| Financing Cash Flow | - | 32.53M | 1.04M | 6.74M | 14.45M |
| Capital Expenditure | -1.92K | -9.34K | -55.04K | -28.47K | - |
| Free Cash Flow | - | -8.68M | -13.64M | -10.52M | -9.68M |
| Net Change in Cash | - | 23.82M | -21.19M | -3.78M | 4.77M |
| Share Buybacks | - | 566.81K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | -1,927.9% | 41.8% | 77.6% |
| Operating Margin % | - | - | -30,526.4% | -409.3% | -778.2% |
| Net Margin % | - | - | -63,986.5% | -2,325.2% | -1,721.0% |
| ROE % | - | -59.9% | 667.8% | -610.7% | -89.0% |
| ROCE % | - | -60.2% | -25.4% | -104.4% | -40.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONCO
Why Is Onco Micro-Cap Stock Surging 50% In Premarket? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOQlBUaDA3WE5qX3gyelJwYlpmZ1VFdGRfQmo5ak1WcDdGbmFLNWpma2RFSHZVN2dWbjhXR3ROTkRHX3RpWHY2ZzRhbzZPOVBxMEM1OXViNUQ5SFM1NzNfX3VKMGozQ0xmaVpXLS1xTjVaYjNEYnpHZzJEalRwN1lHN2xyQXo4OHRDUVJQTk…
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPR1pKemZaU2RCc3lpTUVnN1NmVkhhdUxLUGw1eUZqVVpRNndTWUdoanJSYjc1b0lHWW1jd1JZNE1zOVhsdnZTeGstdGFXeDlsWUNHSm44OTBSZ1djX0pLejdTYmZiTllCeUJMbllBUjBTUThFQ0tVLVdJdmpjT3U4bzU2d2FNMnM5ZWdpRU…
Realbotix has two separate businesses: humanoid robots and adult wellness - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPWUVzMWVoalRSSDFyVEs2SFFuZHZzVk41SlFrNGF2eHdpNlFWSmFnWE9WcTFpS3Z2MjBTTTN2NEp0aXRRMW9TUGVwNF9kTE5aVzVrLTBSQVZkYWNrTUF4OGxtZzZBd1puaFNpeDE4S2pIa0dKNm1kR29BaVAtWVlZY0x2R0JEQldOcUlYRU…
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving? - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPV3AzNGk1REg4NzRPaFBCb3lCV3ktYzdWRno2WUJGRUtrUEp3dGhacUc3OFJPaW5ROWpSZ1g0eDNsQ25TWENvdmNrNzhBU1JoMkxGRjJCdmFDT0Vodk9IWlUwTEhNclFUM2ZzNUd3UFhUcE5vd1hVMnVzVVhoXzFXR1Zxd2htY0lWTGVKbz…
$ONCO stock is down 46% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxObFVTMFNlUTVxeGJSdVh2REczS2Q2cER1MVNBbnlPcHBwUGZLRUQybkNkQ3hEZjU4MUI5M1AyYnJvVGxwWlJRQmtqa2NQdE14bVV4TGQyUnZsc3RsNEZZOUJyNmdpWndQWFREWEJFejVTSERRV3RsMjRWeHN2Rmg5bjlEY0JSclprVTdfVV…
HRT Financial sells $34,299 of Onconetix (NASDAQ:ONCO) stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPYnE5R2hoYVdKeW9rOVNVdmYtbm1WYzZSQ0cyVUZkaFB6aDlOWG5DRFpjMFduVUpGMVBjbWUtWE9SYXRIWEN2bDI2amYxNFpCZ3lSNFA2OW1RSDd4OTdXZHI3VVJxUmcycHM5c0JPQS1aLTNDelR0dUp3Tnp3SXlWV1JOYU1hUElWOXFlNU…
ONCO — Frequently Asked Questions
What is the current share price of ONCO?
As of 2026-08-05 17:25 PDT, ONCO trades at $1.00 on NASDAQ/NYSE. Its 52-week range is $0.75 to $206.00.
What is the market capitalisation of ONCO?
ONCO has a market capitalisation of $31.20K on NASDAQ/NYSE.
What is the return on equity (ROE) of ONCO?
ONCO has a return on equity (ROE) of -89.00%. Its return on capital employed (ROCE) is -40.18%.
Is ONCO a good stock to buy?
This page provides a data-driven analysis of ONCO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.